Comparative Pharmacology
Head-to-head clinical analysis: DESOXYN versus DEXAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOXYN versus DEXAMPEX.
DESOXYN vs DEXAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desoxyn (methamphetamine) is a sympathomimetic amine that promotes release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals, blocks their reuptake, and inhibits monoamine oxidase (MAO) activity. It produces CNS stimulation and peripheral alpha- and beta-adrenergic effects.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Adults: 5-60 mg/day orally in divided doses, typically starting at 5 mg twice daily; maximum 60 mg/day.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 9–14 hours (mean 12 hours) in adults; prolonged in alkaline urine (up to 25–30 hours). Clinically, twice-daily dosing maintains steady state after 2–3 days.
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Renal: ~90% as unchanged drug and metabolites (primarily 4-hydroxyephedrine and 4-hydroxynorephedrine) within 48 hours; urinary pH-dependent: acidic urine increases elimination. Biliary/fecal: minor.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant